Area of research
Oncology · Molecular Biology · cancer
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, Brain Metastases and Treatment, and Cutaneous Melanoma Detection and Management.
Neoadjuvant intent anti-PD-1 immunotherapy for cutaneous squamous cell carcinoma in patients with hematologic malignancy.
Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti–PD-1 therapy.
Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy
Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis
Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis
Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis
Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor–Associated Myocarditis
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis
Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Melanoma central nervous system metastases: current approaches, challenges, and opportunities
Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases.